title: Efficacy and risks of moricizine in inducible sustained ventricular tachycardia.
abstract: OBJECTIVE
  To assess the efficacy and toxicity of moricizine in treating patients with serious ventricular arrhythmias and inducible sustained ventricular tachycardia.
  
  
  METHODS
  Uncontrolled clinical trial.
  
  
  METHODS
  The intensive care and telemetry units of Northwestern Memorial Hospital, St. Francis Hospital and Medical Center, and Lenox Hill Hospital.
  
  
  METHODS
  Twenty-six patients with sustained ventricular arrhythmias or hemodynamically significant nonsustained ventricular tachycardia, most of whom failed therapy with at least one class I antiarrhythmic agent.
  
  
  METHODS
  Patients were treated with moricizine, 400 to 1000 mg/d.
  
  
  METHODS
  Efficacy was assessed by the results of programmed ventricular stimulation done during moricizine therapy.
  
  
  RESULTS
  Seven of the 26 patients (27%) developed life-threatening ventricular proarrhythmia during moricizine loading. Three patients had incessant sustained ventricular tachycardia, two had incessant nonsustained ventricular tachycardia, one had new sustained ventricular tachycardia, and one had new cardiac arrest. One of these patients died of intractable ventricular fibrillation. No clinical or electrophysiologic variables clearly identified those at risk for proarrhythmia. Only 3 of 26 patients (12%) became noninducible on moricizine.
  
  
  CONCLUSIONS
  Moricizine has a low rate of efficacy and carries a considerable risk for life-threatening proarrhythmia in patients with serious ventricular arrhythmias and inducible ventricular tachycardia who have failed therapy with other class I antiarrhythmic agents.
authors.affiliation: Northwestern University Medical School, Chicago, Illinois.
authors.forename: R
authors.initials: R
authors.lastname: Damle
authors.forename: J
authors.initials: J
authors.lastname: Levine
authors.forename: J
authors.initials: J
authors.lastname: Matos
authors.forename: S
authors.initials: S
authors.lastname: Greenberg
authors.forename: R
authors.initials: R
authors.lastname: Brooks
authors.forename: W
authors.initials: W
authors.lastname: Frumkin
authors.forename: J
authors.initials: J
authors.lastname: Goldberger
authors.forename: A H
authors.initials: AH
authors.lastname: Kadish
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D004341:Drug Evaluation; D004558:Electric Stimulation; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016293:Moricizine / Q000009:adverse effects / Q000627:therapeutic use*; D013610:Tachycardia / Q000188:drug therapy*
chemical_list: D000889:Anti-Arrhythmia Agents; D016293:Moricizine